NIH oversight of human gene transfer research involving retroviral, lentiviral, and adeno-associated virus vectors and the role of the NIH recombinant DNA advisory committee

Methods in Enzymology

Volumn 507, Issue , 2012, Pages 313-335

  O'Reilly, Marina ^a   Shipp, Allan ^a   Rosenthal, Eugene ^a   Jambou, Robert ^a   Shih, Tom ^a   Montgomery, Maureen ^a   Gargiulo, Linda ^a   Patterson, Amy ^a   Corrigan Curay, Jacqueline ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

NIH OBA Gene Transfer Policy; Recombinant DNA Advisory Committee

Indexed keywords

ADALIMUMAB; BETA GLOBIN; BLOOD CLOTTING FACTOR 9; HIGH MOBILITY GROUP A2 PROTEIN; LENTIVIRUS VECTOR; PARVOVIRUS VECTOR; RECOMBINANT DNA; RETROVIRUS VECTOR; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR;

ADVISORY COMMITTEE; ARTICLE; BIOETHICS; BIOTECHNOLOGY; CLINICAL TRIAL (TOPIC); DRUG FATALITY; EQUINE INFECTIOUS ANEMIA VIRUS; FELINE IMMUNODEFICIENCY VIRUS; FOOD AND DRUG ADMINISTRATION; HEMOPHILIA B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS; INFECTION; LEUKEMIA; MEDICAL RESEARCH; MURINE LEUKEMIA VIRUS; NATIONAL HEALTH ORGANIZATION; NONHUMAN; POLICY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRODUCT SAFETY; RHEUMATOID ARTHRITIS; SIDE EFFECT; THALASSEMIA; TREATMENT INDICATION; VIRAL GENE DELIVERY SYSTEM; X LINKED SEVERE COMBINED IMMUNODEFICIENCY;

ADENO-ASSOCIATED VIRUS;

EID: 84857623179     PISSN: 00766879     EISSN: 15577988     Source Type: Book Series    
DOI: 10.1016/B978-0-12-386509-0.00016-8     Document Type: Chapter

References (17)

1. J. Areen, and P. King Legal regulation of human gene therapy Hum. Gene Ther. 1 1990 151 161 (Pubitemid 120034725)
2. A. Auiti Gene therapy for immunodeficiency due to adenosine deaminase deficiency N. Engl. J. Med. 360 2009 447 458
3. K. Boztug Stem-cell gene therapy for Wiskott Aldrich syndrome N. Engl. J. Med. 363 2010 1918 1927
4. M. Cavazzano-Calvo Transfusion independence and HMGA2 activation after gene therapy of human Beta-thalassemia Nature 467 2010 318 322
5. A. Fischer Gene therapy for primary adaptive immune deficiencies J. Allergy Clin. Immunol. 127 2011 1356 1359
6. D.S. Fredrickson The Recombinant DNA Controversy: A Memoir, Science, Politics, and the Public Interest 2001 ASM Press Washington, DC 1974-1981
7. E. Gilboa Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells Proc. Natl. Acad. Sci. USA 83 1986 3194 3198
8. S. Hacein-Bey-Abina LMO-2 associated clonal T cell proliferation in two patients after gene therapy for SCID-X1 Science 302 2003 415 419 (Pubitemid 37296260)
9. S. Hacein-Bey-Abina Efficacy of gene therapy for X-linked severe combined immunodeficieny N. Engl. J. Med. 363 2010 355 364
10. S.J. Howe Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy in SCID-X1 patients J. Clin. Invest. 118 2008 3143 3150
11. C. Manno Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response Nat. Med. 12 2006 342 347 (Pubitemid 43355084)
12. F. Mingozzi AAV-1 mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells Blood 114 2009 2077 2086
13. NIH Report Assessment of adenoviral vector safety and toxicity: Report of the National Institutes of Health Recombinant DNA Advisory Committee Hum. Gene Ther. 13 2002 3 13
14. President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research Splicing Life: A Report on the Social and Ethical issues in Genetic Engineering with Human Beings 1982 Washington, DC
15. J.M. Rainsbury Biotechnology on the RAC - FDA/NIH regulation of human gene therapy Food Drug Law J. 55 2000 575 600 (Pubitemid 32063580)
16. S. Stein Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease Nat. Med. 16 2010 198 204
17. R. Weiss Death points to risks in research, one woman's experience in gene therapy highlights weaknesses in the patient safety net Washington Post August 6, 2007